Erasca Q2 loss widens to $44M amid IP threat from Revolution Medicines and securities class action
ERAS has more than doubled off its 52-week low of $1.33.
Summary
Erasca's Q2 2026 10-Q discloses a $44.1 million net loss, $384.3 million in cash, and updated ERAS-0015 data, but the filing is dominated by new disclosures of a securities class action, a stockholder derivative complaint, and IP infringement allegations from Revolution Medicines that threaten the company's lead asset.
Key Events · Earnings and Guidance · ERAS
-
Q2 Net Loss of $44.1M
Driven by higher R&D spending on ERAS-0015 and ERAS-4001, the net loss widened to $44.1 million from $33.9 million a year ago. As of June 30, 2026, cash, equivalents, and marketable securities stood at $384.3 million.
-
IP Infringement Allegations from Revolution Medicines
A letter from Revolution Medicines, dated April 24, 2026, alleges that ERAS-0015 infringes a RevMed patent under the doctrine of equivalents, misappropriates trade secrets, and that Erasca made improper comparative statements. The litigation risk is material.
-
Securities Class Action and Derivative Lawsuits
A securities class action was filed on June 10, 2026, and a stockholder derivative complaint followed in August 2026, both alleging violations of federal securities laws related to ERAS-0015 disclosures. Erasca intends to defend vigorously.
-
Updated ERAS-0015 Phase 1 Data
At the 32 mg QD recommended dose, ERAS-0015 showed a 57% unconfirmed overall response rate at 8 weeks in second-line KRAS G12X pancreatic cancer patients (N=7). Safety remained consistent with prior disclosures.
Analysis · ERAS · Life Sciences
Erasca's 10-Q reveals a $44.1 million quarterly net loss and $384.3 million in cash, but the real story is the new disclosure of a securities class action lawsuit and a letter from Revolution Medicines alleging patent infringement and trade secret misappropriation by ERAS-0015. These legal and IP risks, combined with the termination of the naporafenib program, overshadow the updated clinical data showing a 57% unconfirmed response rate in pancreatic cancer. The company also disclosed a $593.5 million July offering that extends its cash runway, but the litigation overhang and IP uncertainty are the dominant new risks for investors.
At the time of this filing, ERAS was trading at $18.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.4B. The 52-week trading range was $1.33 to $24.28. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.